New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
09:09 EDTBTXBioTime, unit initiates PanC-Dx clinical development in U.S., China
BioTime and its subsidiary OncoCyte announced that OncoCyte has initiated clinical development of its bladder cancer diagnostic test, PanC-Dx, in both the U.S. and China. In the U.S., OncoCyte has entered into a clinical trial agreement with a leading medical institution with an international reputation for excellence and discovery, while in China, OncoCyte has entered into a fee-for-service agreement with China Medicine. The goal of these clinical studies is the testing of OncoCyte’s proprietary diagnostic technology in the most common type of bladder cancer, namely, urothelial carcinoma. Investigators in the collaborating institutions are collecting urine samples from patients at time of bladder cancer diagnosis as well as from those with a risk for recurrent disease. A statistical analysis of these and other results will be performed to determine the overall relative performance of OncoCyte’s PanC-Dx markers. Completion of these studies is expected by late 2014.
News For BTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for BTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use